JP2023543262A5 - - Google Patents

Info

Publication number
JP2023543262A5
JP2023543262A5 JP2023519180A JP2023519180A JP2023543262A5 JP 2023543262 A5 JP2023543262 A5 JP 2023543262A5 JP 2023519180 A JP2023519180 A JP 2023519180A JP 2023519180 A JP2023519180 A JP 2023519180A JP 2023543262 A5 JP2023543262 A5 JP 2023543262A5
Authority
JP
Japan
Application number
JP2023519180A
Other languages
Japanese (ja)
Other versions
JPWO2022067233A5 (https=
JP2023543262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052338 external-priority patent/WO2022067233A2/en
Publication of JP2023543262A publication Critical patent/JP2023543262A/ja
Publication of JPWO2022067233A5 publication Critical patent/JPWO2022067233A5/ja
Publication of JP2023543262A5 publication Critical patent/JP2023543262A5/ja
Pending legal-status Critical Current

Links

JP2023519180A 2020-09-28 2021-09-28 イヌ科動物抗体バリアント Pending JP2023543262A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
US63/084,241 2020-09-28
PCT/US2021/052338 WO2022067233A2 (en) 2020-09-28 2021-09-28 Canine antibody variants

Publications (3)

Publication Number Publication Date
JP2023543262A JP2023543262A (ja) 2023-10-13
JPWO2022067233A5 JPWO2022067233A5 (https=) 2024-09-27
JP2023543262A5 true JP2023543262A5 (https=) 2024-09-27

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519180A Pending JP2023543262A (ja) 2020-09-28 2021-09-28 イヌ科動物抗体バリアント

Country Status (16)

Country Link
EP (1) EP4217384A2 (https=)
JP (1) JP2023543262A (https=)
KR (1) KR20230079148A (https=)
CN (1) CN116438196A (https=)
AR (1) AR123636A1 (https=)
AU (1) AU2021349301A1 (https=)
BR (1) BR112023005393A2 (https=)
CA (1) CA3194936A1 (https=)
CL (2) CL2023000878A1 (https=)
CO (1) CO2023004102A2 (https=)
EC (1) ECSP23030271A (https=)
IL (1) IL301413A (https=)
MX (1) MX2023003624A (https=)
PE (1) PE20231374A1 (https=)
TW (1) TW202229337A (https=)
WO (1) WO2022067233A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
KR20250026186A (ko) * 2022-06-21 2025-02-25 조에티스 서비시즈 엘엘씨 갯과 항체 돌연변이체
JP2026508096A (ja) 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
EP3887397A1 (en) * 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体

Similar Documents

Publication Publication Date Title
BR112021014123A2 (https=)
JP2023543262A5 (https=)
BR112023011738A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR112023011610A2 (https=)
BR102021020147A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012107A2 (https=)
BR102021012003A2 (https=)